BRPI0820749B8 - derivados de peptídeo mimético de eritropoietina e seu sal farmaceuticamente aceitável, método para preparação dos referidos derivados, composição farmacêutica e usos dos mesmos - Google Patents

derivados de peptídeo mimético de eritropoietina e seu sal farmaceuticamente aceitável, método para preparação dos referidos derivados, composição farmacêutica e usos dos mesmos

Info

Publication number
BRPI0820749B8
BRPI0820749B8 BRPI0820749A BRPI0820749A BRPI0820749B8 BR PI0820749 B8 BRPI0820749 B8 BR PI0820749B8 BR PI0820749 A BRPI0820749 A BR PI0820749A BR PI0820749 A BRPI0820749 A BR PI0820749A BR PI0820749 B8 BRPI0820749 B8 BR PI0820749B8
Authority
BR
Brazil
Prior art keywords
derivatives
mimetic peptide
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
Prior art date
Application number
BRPI0820749A
Other languages
English (en)
Inventor
Lü Aifeng
Sun Changan
Jiang Tao
Wu Wentao
Wang Yali
Original Assignee
Jiangsu Hansoh Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Co Ltd
Publication of BRPI0820749A2 publication Critical patent/BRPI0820749A2/pt
Publication of BRPI0820749B1 publication Critical patent/BRPI0820749B1/pt
Publication of BRPI0820749B8 publication Critical patent/BRPI0820749B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

derivados de peptídeo mimético de eritropoietina e seu sal farmaceuticamente aceitável, método de preparação dos referidos derivados, composição farmacêutica e usos dos mesmos. a presente invenção refere-se a um derivado de peptídeo mimético de epo definido na fórmula (i) e seus sais farmacêuticos, a preparação do mesmo, em que r1, r2, r3, r4, r5, n1, n2 são definidos como descrito na descrição. uma composição compreendendo um derivado de peptídeo mimético de epo definido na fórmula (i) e seus sais farmacêuticos. os usos dos derivados e seus sais farmacêuticos, bem como os usos da composição descrita acima no tratamento de doenças caracterizadas por uma deficiência em epo ou uma baixa ou defectiva população de células sanguíneas vermelhas. r1-r2-(ch2)n1-r3-(ch2)n2-r4-r5 (i).
BRPI0820749A 2007-12-12 2008-11-24 derivados de peptídeo mimético de eritropoietina e seu sal farmaceuticamente aceitável, método para preparação dos referidos derivados, composição farmacêutica e usos dos mesmos BRPI0820749B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNA2007101987519A CN101456911A (zh) 2007-12-12 2007-12-12 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
CN200710198751.9 2007-12-12
PCT/CN2008/001909 WO2009079910A1 (fr) 2007-12-12 2008-11-24 Dérivé de peptide mimétique d'érythropoïétine et son sel pharmaceutique, préparation et utilisations

Publications (3)

Publication Number Publication Date
BRPI0820749A2 BRPI0820749A2 (pt) 2015-06-16
BRPI0820749B1 BRPI0820749B1 (pt) 2020-11-24
BRPI0820749B8 true BRPI0820749B8 (pt) 2021-05-25

Family

ID=40768057

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820749A BRPI0820749B8 (pt) 2007-12-12 2008-11-24 derivados de peptídeo mimético de eritropoietina e seu sal farmaceuticamente aceitável, método para preparação dos referidos derivados, composição farmacêutica e usos dos mesmos

Country Status (15)

Country Link
US (1) US8642545B2 (pt)
EP (1) EP2233504B1 (pt)
JP (1) JP5448099B2 (pt)
KR (1) KR101646929B1 (pt)
CN (2) CN101456911A (pt)
AU (1) AU2008341661B9 (pt)
BR (1) BRPI0820749B8 (pt)
CA (1) CA2708819C (pt)
ES (1) ES2541139T3 (pt)
MX (1) MX2010006436A (pt)
RU (1) RU2493168C2 (pt)
TW (1) TWI419706B (pt)
UA (1) UA102236C2 (pt)
WO (1) WO2009079910A1 (pt)
ZA (1) ZA201003998B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2709648A4 (en) * 2011-05-19 2015-04-08 Geysen Hendrik M COMPOUNDS FOR BINDING TO THE ERYTHROPOIETIN RECEPTOR
WO2013158871A1 (en) 2012-04-20 2013-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of erythropoietin and derivatives for treating hypertension
CN103450348B (zh) * 2012-05-29 2016-03-30 中国人民解放军军事医学科学院毒物药物研究所 一种促红细胞生成素模拟肽、其制备方法和用途
CN103536900B (zh) * 2012-07-16 2017-06-16 江苏豪森药业集团有限公司 含有促红细胞生成素模拟肽的药物组合物
CN103570834A (zh) * 2012-07-19 2014-02-12 江苏豪森药业股份有限公司 甲氧基聚乙二醇修饰的促红细胞生成素模拟肽衍生物
CN112245586A (zh) * 2013-03-15 2021-01-22 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
CN104231039A (zh) * 2013-06-08 2014-12-24 江苏豪森药业股份有限公司 用于合成促红细胞生成素模拟肽衍生物的功能小分子及其制备方法
CN105085653B (zh) * 2015-08-26 2019-01-08 天津药物研究院有限公司 一种促红细胞生成素模拟肽及其制备方法和应用
CN106608913B (zh) * 2015-10-22 2020-05-05 天津药物研究院有限公司 一种1，2，3-丙三酸偶联的epo拟肽衍生物及其制备方法和应用
CN106608912B (zh) * 2015-10-22 2019-09-20 天津药物研究院有限公司 一种脂肪二羧酸偶联的epo模拟肽衍生物及其制备方法和应用
CN105367629B (zh) * 2015-11-09 2019-01-08 天津药物研究院有限公司 一种促红细胞生成素模拟肽以及其制备方法和用途
CN106928338A (zh) * 2015-12-31 2017-07-07 杭州阿德莱诺泰制药技术有限公司 促红细胞生成素肽及衍生物和聚合物、制备方法和应用
JP2019532618A (ja) 2016-07-12 2019-11-14 ヘキサル・アクチェンゲゼルシャフト 低アセチル化率シアル酸残基を有する糖タンパク質
CN108236717A (zh) * 2016-12-27 2018-07-03 江苏豪森药业集团有限公司 聚乙二醇连接臂与所修饰多肽药物的偶合物
JP7445978B2 (ja) * 2018-09-14 2024-03-08 エポメッド株式会社 抗エリスロポエチン受容体ペプチド
KR102073886B1 (ko) 2019-05-02 2020-02-05 주식회사 미래와바다 잘피이식용 다공질 패널
CN114601916B (zh) * 2022-04-12 2024-04-16 江苏豪森药业集团有限公司 一种培化西海马肽注射制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
CA2223833C (en) * 1995-06-07 2010-12-21 Nicholas C. Wrighton Compounds and peptides that bind to the erythropoietin receptor
EP0964702B1 (en) * 1996-08-02 2006-10-04 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
ME00673B (me) * 2000-05-15 2011-12-20 Hoffmann La Roche Nova farmaceutska smjesa
CN1169827C (zh) * 2001-08-07 2004-10-06 沈阳三生制药股份有限公司 一种增强多肽在体内稳定性药物的生产方法及其应用
AU2004238868B2 (en) * 2003-05-12 2010-01-21 Affymax, Inc. Peptides that bind to the erythropoietin receptor
ATE428727T1 (de) * 2003-05-12 2009-05-15 Affymax Inc Neue, an den erythropoietinrezeptor bindende peptide
CN1820024B (zh) * 2003-05-12 2011-06-22 阿费麦克斯公司 新的聚(乙二醇)修饰的化合物及其用途
CN100362019C (zh) * 2004-03-02 2008-01-16 成都生物制品研究所 聚乙二醇修饰后具有体内生理活性的重组促红细胞生成素
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド

Also Published As

Publication number Publication date
US8642545B2 (en) 2014-02-04
EP2233504A4 (en) 2011-03-09
JP2011506350A (ja) 2011-03-03
EP2233504B1 (en) 2015-04-01
RU2010123466A (ru) 2012-01-20
CN101675080A (zh) 2010-03-17
UA102236C2 (uk) 2013-06-25
EP2233504A1 (en) 2010-09-29
KR20110025731A (ko) 2011-03-11
JP5448099B2 (ja) 2014-03-19
US20100323949A1 (en) 2010-12-23
CN101456911A (zh) 2009-06-17
ZA201003998B (en) 2011-10-26
BRPI0820749B1 (pt) 2020-11-24
WO2009079910A1 (fr) 2009-07-02
MX2010006436A (es) 2010-10-06
RU2493168C2 (ru) 2013-09-20
AU2008341661B9 (en) 2013-08-15
TW201002352A (en) 2010-01-16
CA2708819C (en) 2018-05-15
AU2008341661B2 (en) 2013-08-08
CN101675080B (zh) 2012-07-11
HK1136837A1 (zh) 2010-07-09
WO2009079910A8 (zh) 2009-11-19
KR101646929B1 (ko) 2016-08-09
TWI419706B (zh) 2013-12-21
AU2008341661A1 (en) 2009-07-02
ES2541139T3 (es) 2015-07-16
CA2708819A1 (en) 2009-07-02
BRPI0820749A2 (pt) 2015-06-16

Similar Documents

Publication Publication Date Title
BRPI0820749B8 (pt) derivados de peptídeo mimético de eritropoietina e seu sal farmaceuticamente aceitável, método para preparação dos referidos derivados, composição farmacêutica e usos dos mesmos
BRPI0910832B8 (pt) derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.
BRPI0718813B8 (pt) compostos derivados de 1,1-dióxido de 1,4-benzotiepina, medicamento que os compreendem e seus usos
BR112019022512A2 (pt) Compostos de heteroarila bicíclica fundida 6-6 e seu uso como inibidores de lats
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
BR112014008686A2 (pt) derivados de oxazina e uso dos mesmos no tratamento de doença
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BR112015011158A8 (pt) triazolopirazina, seu uso e preparação farmacêutica
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
BR112015018751A2 (pt) derivados de piridazinona macrocíclicos
BR112014010590A2 (pt) 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose
BR112015015635A8 (pt) composto, método de preparação dos compostos, composição farmacêutica e método in vitro de previsão
BR112012012947B8 (pt) sal de hemitartarato e composição farmacêutica compreendendo o mesmo
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
BR112014011850A8 (pt) Derivados de aminopirimidina, seus usos, e composição farmacêutica
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
BR112014015720A8 (pt) derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases
BR112014009717A2 (pt) "derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica"
BR112013019160A2 (pt) novos compostos, composição farmacêutica, uso, processos e métodos
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BRPI0412997A (pt) derivados de dióxido de tiazol-benzoisotiazol substituìdos, método para produzir os mesmos e seu uso
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
BRPI0713132B8 (pt) compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos
BRPI0514310A (pt) 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/505 (2006.01), A61K 47/55 (2017.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN)

B25G Requested change of headquarter approved

Owner name: JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/11/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF